{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:02:01Z","timestamp":1784224921657,"version":"3.55.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.iac.2018.04.005","type":"journal-article","created":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T21:27:24Z","timestamp":1528579644000},"page":"411-428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Kit Mutations"],"prefix":"10.1016","volume":"38","author":[{"given":"Lorenzo","family":"Falchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.iac.2018.04.005_bib1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.iac.2018.04.005_bib2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","article-title":"Epidemiology, prognosis, and risk factors in mastocytosis","volume":"34","author":"Brockow","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"10.1016\/j.iac.2018.04.005_bib3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/pbc.22125","article-title":"Pediatric-onset mastocytosis: a long term clinical follow-up and correlation with bone marrow histopathology","volume":"53","author":"Uzzaman","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"10.1016\/j.iac.2018.04.005_bib4","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iac.2018.04.005_bib5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/jcp.2003.014860","article-title":"Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge","volume":"57","author":"Horny","year":"2004","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.iac.2018.04.005_bib6","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017"},{"issue":"1","key":"10.1016\/j.iac.2018.04.005_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.iac.2013.09.001","article-title":"Mastocytosis","volume":"34","author":"Carter","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"10.1016\/j.iac.2018.04.005_bib8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.clinthera.2013.04.001","article-title":"Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes","volume":"35","author":"Picard","year":"2013","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.iac.2018.04.005_bib9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11154-016-9394-8","article-title":"Flushing in (neuro) endocrinology","volume":"17","author":"Hannah-Shmouni","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"10.1016\/j.iac.2018.04.005_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000048188","article-title":"Mastocytosis: mediator-related signs and symptoms","volume":"127","author":"Castells","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10.1016\/j.iac.2018.04.005_bib11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000048185","article-title":"Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression","volume":"127","author":"Valent","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"10.1016\/j.iac.2018.04.005_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.23380","article-title":"Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components","volume":"88","author":"Wang","year":"2013","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.iac.2018.04.005_bib13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1398-9995.2012.02812.x","article-title":"Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis","volume":"67","author":"Alvarez-Twose","year":"2012","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.iac.2018.04.005_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European competence network on mastocytosis; the American academy of allergy, asthma & immunology; and the European academy of allergology and clinical immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2018.04.005_bib15","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1365-2362.2009.02184.x","article-title":"Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology","volume":"39","author":"Sperr","year":"2009","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"10.1016\/j.iac.2018.04.005_bib16","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/00000478-199809000-00013","article-title":"Diagnostic value of immunostaining for tryptase in patients with mastocytosis","volume":"22","author":"Horny","year":"1998","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.iac.2018.04.005_bib17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1053\/hupa.2001.24319","article-title":"Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117\/Kit, and bcl-x(L)","volume":"32","author":"Jordan","year":"2001","journal-title":"Hum Pathol"},{"issue":"10","key":"10.1016\/j.iac.2018.04.005_bib18","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/01.pas.0000138181.89743.7b","article-title":"CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens","volume":"28","author":"Sotlar","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.iac.2018.04.005_bib19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1525-1578(10)60552-1","article-title":"c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation","volume":"7","author":"Yanagihori","year":"2005","journal-title":"J\u00a0Mol Diagn"},{"issue":"11","key":"10.1016\/j.iac.2018.04.005_bib20","first-page":"2207","article-title":"Organization and nucleotide sequence of the human KIT (mast\/stem cell growth factor receptor) proto-oncogene","volume":"7","author":"Giebel","year":"1992","journal-title":"Oncogene"},{"issue":"6185","key":"10.1016\/j.iac.2018.04.005_bib21","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/335088a0","article-title":"The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus","volume":"335","author":"Chabot","year":"1988","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.iac.2018.04.005_bib22","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem cell factor receptor\/c-Kit: from basic science to clinical implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol Rev"},{"issue":"23","key":"10.1016\/j.iac.2018.04.005_bib23","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.3748\/wjg.v18.i23.2929","article-title":"Stem cell factor-mediated wild-type KIT receptor activation is critical for gastrointestinal stromal tumor cell growth","volume":"18","author":"Bai","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.iac.2018.04.005_bib24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.iac.2014.01.002","article-title":"Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms","volume":"34","author":"Cruse","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"10.1016\/j.iac.2018.04.005_bib25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1242\/dev.118.3.705","article-title":"W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis","volume":"118","author":"Duttlinger","year":"1993","journal-title":"Development"},{"issue":"4","key":"10.1016\/j.iac.2018.04.005_bib26","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.iac.2018.04.005_bib27","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/gene.2010.35","article-title":"Mast cell homeostasis and the JAK-STAT pathway","volume":"11","author":"Morales","year":"2010","journal-title":"Genes Immun"},{"issue":"2","key":"10.1016\/j.iac.2018.04.005_bib28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0301-472X(99)00145-9","article-title":"Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T\u00a0cells, B cells, and myelomonocytic cells in patients with mastocytosis","volume":"28","author":"Akin","year":"2000","journal-title":"Exp Hematol"},{"issue":"8","key":"10.1016\/j.iac.2018.04.005_bib29","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood.V87.8.3117.bloodjournal8783117","article-title":"A\u00a0point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells","volume":"87","author":"Piao","year":"1996","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iac.2018.04.005_bib30","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1523-1747.1998.00414.x","article-title":"Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior","volume":"111","author":"Buttner","year":"1998","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2018.04.005_bib31","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.iac.2018.04.005_bib32","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9440(10)63870-9","article-title":"One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes","volume":"162","author":"Sotlar","year":"2003","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.iac.2018.04.005_bib33","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2018.04.005_bib34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1006\/bcmd.1998.0191","article-title":"In\u00a0vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation","volume":"24","author":"Beghini","year":"1998","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"10.1016\/j.iac.2018.04.005_bib35","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"4","key":"10.1016\/j.iac.2018.04.005_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/1096-8652(200012)65:4<307::AID-AJH10>3.0.CO;2-F","article-title":"Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His","volume":"65","author":"Pullarkat","year":"2000","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.iac.2018.04.005_bib37","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1365-2141.1997.d01-2042.x","article-title":"A\u00a0new c-kit mutation in a case of aggressive mast cell disease","volume":"96","author":"Pignon","year":"1997","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.iac.2018.04.005_bib38","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2018.04.005_bib39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000096907","article-title":"C-kit Asp-816-Val mutation analysis in patients with mastocytosis","volume":"214","author":"Verzijl","year":"2007","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.iac.2018.04.005_bib40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.iac.2014.01.009","article-title":"Molecular defects in mastocytosis: KIT and beyond KIT","volume":"34","author":"Bibi","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"10.1016\/j.iac.2018.04.005_bib41","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1053\/j.gastro.2005.06.060","article-title":"Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis","volume":"129","author":"Hartmann","year":"2005","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.iac.2018.04.005_bib42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A\u00a0novel K509I mutation of KIT identified in familial mastocytosis-in\u00a0vitro and in\u00a0vivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.iac.2018.04.005_bib43","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A\u00a0novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iac.2018.04.005_bib44","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1136\/jmg.2003.015156","article-title":"A\u00a0germline mutation in KIT in familial diffuse cutaneous mastocytosis","volume":"41","author":"Tang","year":"2004","journal-title":"J\u00a0Med Genet"},{"issue":"5","key":"10.1016\/j.iac.2018.04.005_bib45","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/path.2677","article-title":"Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)","volume":"220","author":"Sotlar","year":"2010","journal-title":"J\u00a0Pathol"},{"issue":"6","key":"10.1016\/j.iac.2018.04.005_bib46","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1200\/JCO.2012.41.9549","article-title":"Mast cell sarcoma: a rare and aggressive entity\u2013report of two cases and review of the literature","volume":"31","author":"Georgin-Lavialle","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3\u20134","key":"10.1016\/j.iac.2018.04.005_bib47","first-page":"210","article-title":"Identification of a polymorphism in the transmembrane domain of the protooncogene c-kit in healthy subjects","volume":"13","author":"Nagata","year":"1996","journal-title":"Exp Clin Immunogenet"},{"issue":"6","key":"10.1016\/j.iac.2018.04.005_bib48","doi-asserted-by":"crossref","first-page":"e1002068","DOI":"10.1371\/journal.pcbi.1002068","article-title":"Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms","volume":"7","author":"Laine","year":"2011","journal-title":"PLoS Comput Biol"},{"issue":"7","key":"10.1016\/j.iac.2018.04.005_bib49","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0145-2126(01)00028-5","article-title":"Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy","volume":"25","author":"Longley","year":"2001","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.iac.2018.04.005_bib50","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.13560","article-title":"Concurrent activating KIT mutations in systemic mastocytosis","volume":"173","author":"Lasho","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.iac.2018.04.005_bib51","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1084\/jem.20050807","article-title":"Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation","volume":"202","author":"Zappulla","year":"2005","journal-title":"J\u00a0Exp Med"},{"issue":"6","key":"10.1016\/j.iac.2018.04.005_bib52","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood-2008-11-189605","article-title":"Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit","volume":"117","author":"Gerbaulet","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.iac.2018.04.005_bib53","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.iac.2018.04.005_bib54","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","article-title":"In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells","volume":"120","author":"Soucie","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.iac.2018.04.005_bib55","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.iac.2018.04.005_bib56","doi-asserted-by":"crossref","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis","volume":"7","author":"Traina","year":"2012","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.iac.2018.04.005_bib57","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2018.04.005_bib58","doi-asserted-by":"crossref","first-page":"e85362","DOI":"10.1371\/journal.pone.0085362","article-title":"ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases","volume":"9","author":"Damaj","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.iac.2018.04.005_bib59","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2010.031690","article-title":"Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis","volume":"96","author":"Wilson","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.iac.2018.04.005_bib60","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3324\/haematol.2013.095133","article-title":"SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes","volume":"99","author":"Hanssens","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.iac.2018.04.005_bib61","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.iac.2018.04.005_bib62","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"10.1016\/j.iac.2018.04.005_bib63","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2353\/jmoldx.2006.060022","article-title":"Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology","volume":"8","author":"Akin","year":"2006","journal-title":"J\u00a0Mol Diagn"},{"issue":"1","key":"10.1016\/j.iac.2018.04.005_bib64","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.iac.2018.04.005_bib65","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.2012.01789.x","article-title":"Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis","volume":"89","author":"Kristensen","year":"2012","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.iac.2018.04.005_bib66","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/all.12409","article-title":"The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease","volume":"69","author":"Hoermann","year":"2014","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.iac.2018.04.005_bib67","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10428190400010775","article-title":"Mastocytosis: pathology, genetics, and current options for therapy","volume":"46","author":"Valent","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.iac.2018.04.005_bib68","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-62703-357-2_4","article-title":"c-kit mutational analysis in paraffin material","volume":"999","author":"Sotlar","year":"2013","journal-title":"Methods Mol Biol"},{"issue":"5","key":"10.1016\/j.iac.2018.04.005_bib69","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2353\/jmoldx.2006.060089","article-title":"Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia","volume":"8","author":"Corless","year":"2006","journal-title":"J\u00a0Mol Diagn"},{"issue":"12","key":"10.1016\/j.iac.2018.04.005_bib70","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1373\/clinchem.2006.068205","article-title":"Sensitive detection of KIT D816V in patients with mastocytosis","volume":"52","author":"Tan","year":"2006","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.iac.2018.04.005_bib71","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23672","article-title":"Mastocytosis Centre OUH. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis","volume":"89","author":"Kristensen","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.iac.2018.04.005_bib72","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/jcp.2007.047928","article-title":"Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR","volume":"61","author":"Schumacher","year":"2008","journal-title":"J\u00a0Clin Pathol"},{"issue":"2","key":"10.1016\/j.iac.2018.04.005_bib73","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J\u00a0Mol Diagn"},{"issue":"10","key":"10.1016\/j.iac.2018.04.005_bib74","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/all.12436","article-title":"Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis","volume":"69","author":"Valent","year":"2014","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.iac.2018.04.005_bib75","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000349986","article-title":"KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis","volume":"226","author":"Kristensen","year":"2013","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.iac.2018.04.005_bib76","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0889-8588(05)70298-7","article-title":"Gastrointestinal abnormalities and involvement in systemic mastocytosis","volume":"14","author":"Jensen","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"10.1016\/j.iac.2018.04.005_bib77","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/1042819032000140979","article-title":"Splenic mastocytosis: report of two cases and detection of the transforming somatic C-KIT mutation D816V","volume":"45","author":"Wimazal","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.iac.2018.04.005_bib78","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/mp.53.4.188","article-title":"Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia","volume":"53","author":"Sotlar","year":"2000","journal-title":"Mol Pathol"},{"issue":"3","key":"10.1016\/j.iac.2018.04.005_bib79","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2017.277897","article-title":"Digital PCR: a sensitive and precise method for KIT D816V quantification in mastocytosis","volume":"64","author":"Greiner","year":"2017","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/j.iac.2018.04.005_bib80","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.iac.2018.04.005_bib81","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"issue":"11","key":"10.1016\/j.iac.2018.04.005_bib82","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/all.13187","article-title":"Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis","volume":"72","author":"Kristensen","year":"2017","journal-title":"Allergy"},{"issue":"12","key":"10.1016\/j.iac.2018.04.005_bib83","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost","year":"2002","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.iac.2018.04.005_bib84","first-page":"317","article-title":"Not all c-kit mutations can be corrected by imatinib","volume":"87","author":"Lasota","year":"2007","journal-title":"Lab Invest"},{"issue":"12","key":"10.1016\/j.iac.2018.04.005_bib85","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.iac.2018.04.005_bib86","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.iac.2018.04.005_bib87","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.iac.2018.04.005_bib88","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12185-008-0166-4","article-title":"Advanced mast cell disease: an Italian Hematological Multicenter experience","volume":"88","author":"Pagano","year":"2008","journal-title":"Int J Hematol"},{"issue":"5","key":"10.1016\/j.iac.2018.04.005_bib89","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2008-03-147785","article-title":"Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation","volume":"112","author":"Hoffmann","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.iac.2018.04.005_bib90","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis","volume":"30","author":"Alvarez-Twose","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.iac.2018.04.005_bib91","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-0609.2011.01598.x","article-title":"A\u00a0case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib","volume":"86","author":"Mital","year":"2011","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.iac.2018.04.005_bib92","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jmgm.2004.04.003","article-title":"Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase","volume":"23","author":"Foster","year":"2004","journal-title":"J\u00a0Mol Graph Model"},{"issue":"1","key":"10.1016\/j.iac.2018.04.005_bib93","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0609.2012.01761.x","article-title":"Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor","volume":"89","author":"Georgin-Lavialle","year":"2012","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.iac.2018.04.005_bib94","first-page":"17","article-title":"PKC412\u2013a protein kinase inhibitor with a broad therapeutic potential","volume":"15","author":"Fabbro","year":"2000","journal-title":"Anticancer Drug Des"},{"issue":"2","key":"10.1016\/j.iac.2018.04.005_bib95","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.iac.2018.04.005_bib96","first-page":"73","article-title":"Midostaurin: an emerging treatment for acute myeloid leukemia patients","volume":"7","author":"Gallogly","year":"2016","journal-title":"J\u00a0Blood Med"},{"issue":"26","key":"10.1016\/j.iac.2018.04.005_bib97","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2018.04.005_bib98","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.iac.2018.04.005_bib99","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.leukres.2006.04.005","article-title":"Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit","volume":"30","author":"Verstovsek","year":"2006","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.iac.2018.04.005_bib100","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.iac.2018.04.005_bib101","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s00432-015-1988-0","article-title":"Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study","volume":"141","author":"Hochhaus","year":"2015","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.iac.2018.04.005_bib102","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1158\/1535-7163.MCT-13-0397","article-title":"Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing beta-catenin signaling","volume":"13","author":"Jin","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"10.1016\/j.iac.2018.04.005_bib103","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3324\/haematol.2012.079202","article-title":"Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V","volume":"98","author":"Gleixner","year":"2013","journal-title":"Haematologica"},{"issue":"414","key":"10.1016\/j.iac.2018.04.005_bib104","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A\u00a0precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.iac.2018.04.005_bib105","first-page":"2","article-title":"Clinical activity in a phase 1 study of Blu-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (AdvSM)","volume":"130","author":"DeAngelo","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.iac.2018.04.005_bib106","doi-asserted-by":"crossref","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.iac.2018.04.005_bib107","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.21894","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study","volume":"85","author":"Paul","year":"2010","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.iac.2018.04.005_bib108","doi-asserted-by":"crossref","first-page":"e2266","DOI":"10.1371\/journal.pone.0002266","article-title":"Case-control cohort study of patients' perceptions of disability in mastocytosis","volume":"3","author":"Hermine","year":"2008","journal-title":"PLoS One"},{"issue":"10069","key":"10.1016\/j.iac.2018.04.005_bib109","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.iac.2018.04.005_bib110","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/leu.2012.218","article-title":"Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation","volume":"27","author":"Bai","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.iac.2018.04.005_bib111","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V128.22.1965.1965","article-title":"The multi-kinase inhibitor DCC-2618 inhibits proliferation and survival of neoplastic mast cells and other cell types involved in systemic mastocytosis","volume":"128","author":"Schneeweiss","year":"2016","journal-title":"Blood"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856118300316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856118300316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T10:49:34Z","timestamp":1661424574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856118300316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":111,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0889856118300316"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2018.04.005","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kit Mutations","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2018.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}